AZB & Partners has acted for global investment giant KKR on its acquisition of a “significant minority stake” in AI-driven healthcare revenue cycle solutions provider Infinx, which was guided by Argus Partners.

Norwest Venture Partners, an existing shareholder, also participated in the investment round and was represented by Shardul Amarchand Mangaldas & Co.

Reports suggest that KKR’s acquisition, to be made through its Asian Fund IV, will be around $150 million.

“Through this investment, KKR will leverage its extensive experience in the global healthcare and technology sectors to accelerate Infinx’s growth, expand the company’s network, and support bolt-on acquisitions,” the global investment firm said in a statement.

Infinx is the latest Indian company to enter KKR’s healthcare portfolio, which includes Healthium Medtech, a leading Indian medical devices company; Max Healthcare, a private hospital network in India; and JB, a pharmaceutical company specializing in branded formulations in India.

AZB’s deal team included senior partner Nandish Vyas, partner Malaveeka Chakravarthy, senior associates Ashutosh Merchant and Anish Patel, and associate Freya Irani. Partners Shivanand Nayak (finance), Nishanth Ravindran (employment) and Bharat V Budholia (competition) also assisted on the deal.

The Argus team that represented Infinx and its promoters was led by partners Abhinav Bhalaik, Armaan Patkar and Vallishree Chandra, and included principal associate Mayank Jhunjhunwala, senior associates Ishita Agarwal and Himani Shah, and associates Ayushi Khetan, Kanishk Gambhir and Samridhi Kapoor.